Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONMED Corp Director's Dealing 2013

Jun 10, 2013

31971_dirs_2013-06-10_d79d49ad-7431-4fed-bfad-a468a6f17f44.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2013-06-07

Reporting Person: CORASANTI EUGENE R (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-06-07 Common Stock M 500 $26.69 Acquired 76759 Direct
2013-06-07 Common Stock F 437 $32.38 Disposed 76322 Direct
2013-06-07 Common Stock M 500 $16.46 Acquired 76822 Direct
2013-06-07 Common Stock F 321 $32.38 Disposed 76501 Direct
2013-06-07 Common Stock M 500 $19.26 Acquired 77001 Direct
2013-06-07 Common Stock F 352 $32.38 Disposed 76649 Direct
2013-06-07 Common Stock M 500 $27.63 Acquired 77149 Direct
2013-06-07 Common Stock F 447 $32.38 Disposed 76702 Direct
2013-06-07 Common Stock M 2500 $26.09 Acquired 79202 Direct
2013-06-07 Common Stock F 2144 $32.38 Disposed 77058 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-06-07 Sars (Stock Appreciation Rights) $26.69 M 500 Disposed 2018-06-01 Common Stock (500) Direct
2013-06-07 Sars (Stock Appreciation Rights) $16.46 M 500 Disposed 2019-06-01 Common Stock (500) Direct
2013-06-07 Sars (Stock Appreciation Rights) $19.26 M 500 Disposed 2020-06-01 Common Stock (500) Direct
2013-06-07 Sars (Stock Appreciation Rights) $27.63 M 500 Disposed 2021-06-01 Common Stock (500) Direct
2013-06-07 Sars (Stock Appreciation Rights) $26.09 M 2500 Disposed 2022-06-01 Common Stock (2500) Direct

Footnotes

F1: The stock appreciation rights ("SARs") were granted under the Company's 2006 Stock Incentive Plan and generally vest in equal
amounts over a five year period.

F2: The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

F3: The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the SARs generally vesting 100% after a one year period.